AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Venclexta (venetoclax) by Year
Venclexta (venetoclax) — U.S. reported growth YoY (%) (%)
AbbVie Venclexta (venetoclax): 5.9% in FY2025, down 7.6 pts from a year earlier.
Latest, FY2025
5.9%
Period ended Dec 31, 2025
Change on a year earlier
-7.6 pts
13.5% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Venclexta | 1,306 | 1,486 | 2,792 | 5.9 | 10.2 | 8.1 | 9.8 | 7.9”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Venclexta (venetoclax) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.9% | -7.6 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 13.5% | +5.7 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 7.8% | -0.2 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 8.0% | -8.1 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 16.1% | -38.3 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 54.4% | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
Cite this data
StockData. (2026). AbbVie Venclexta (venetoclax) (%), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/venclexta-us-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.